about
Imatinib for treating newly diagnosed chronic myeloid leukemia patientsImatinib for treating patients with chronic myelogeneous leukemiaABL tyrosine kinases: evolution of function, regulation, and specificityLong-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling.Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinibTargeted inhibition of kinases in cancer therapyBosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitorsBosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitorsInduction of Apoptosis and Antitumor Activity of Eel Skin Mucus, Containing Lactose-Binding Molecules, on Human Leukemic K562 CellsA NOX2/Egr-1/Fyn pathway delineates new targets for TKI-resistant malignanciesBosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failureLymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicityManagement of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors.Therapy of chronic myeloid leukemia: twilight of the imatinib era?Hematopoietic stem cell transplantation in the era of tyrosine kinase inhibitors.Integrated microfluidic and imaging platform for a kinase activity radioassay to analyze minute patient cancer samples.On the stem cell origin of cancerClinical Pharmacokinetics and Pharmacodynamics of Bosutinib.Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinib.p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia.The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL.New effective inhibitors of the Abelson kinase.Organopalladium compound 7b targets mitochondrial thiols and induces caspase-dependent apoptosis in human myeloid leukemia cells.Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myleloid leukemia cells.Hydroxychavicol, a Piper betle leaf component, induces apoptosis of CML cells through mitochondrial reactive oxygen species-dependent JNK and endothelial nitric oxide synthase activation and overrides imatinib resistance.Primary imatinib failure rescued by dasatinib and maintained by reintroduction of imatinib.Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha.Bortezomib induces apoptosis by interacting with JAK/STAT pathway in K562 leukemic cells.Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study.Therapeutic potential of apigenin, a plant flavonoid, for imatinib-sensitive and resistant chronic myeloid leukemia cells.Release of intracellular calcium primes chronic myeloid leukaemia cells for tyrosine kinase inhibitor-induced apoptosis.A mathematical model with time-varying delays in the combined treatment of chronic myeloid leukemia
P2860
Q24186877-D02D6CC0-BFA9-44B4-9957-C315EE44570FQ24241730-40BDCAB1-344A-44EA-AA6B-3A66E55B791AQ24299738-1AB2BF8E-3D0E-49A6-81AF-9A002CE42634Q33434675-6B0D8E69-342C-4333-B061-014C2110B316Q33753325-EE6317F6-EDA3-4A62-90B3-709B9D13BEC4Q34210528-EDB2479C-0A23-4AD4-B4FA-A9F87C24AEA2Q34683348-21EA2D1C-7AEE-41A7-827F-FCCCE06D6056Q34763374-AEDD4ACB-A0E1-4C02-82E6-1956DBDF783EQ35595870-82530476-1BC5-4604-BCEA-ABD6D664023EQ35743878-E92B8CDD-7416-47CB-8B45-C5AC114FF2DAQ35790806-31EABA03-C274-480B-A0EA-E4D55D190654Q36414254-1F3E72B1-F82F-455D-ACB9-D36C436C520EQ37027759-D2C1D9EB-1C64-455C-B531-D9E2E5C60C9FQ37352396-3DA5D6A9-2B54-4170-81AA-879EDFB305DFQ37360559-A88921C4-FDE9-4018-A86E-A6502A00BED6Q37593435-DAACC95E-F857-4509-9A36-26225F33B80EQ37657492-6F8A97B8-24E7-46D7-B8FD-36EAE00737F1Q37707912-001D5038-EBB7-47D2-99E4-D5299B792DF8Q37739713-24AF27D2-8354-45DC-A951-6B395300FF9AQ38817367-81EF7296-30EA-4B89-9144-46F419C8D5D5Q39410543-D2D9D014-860B-4A86-A9FF-D0D3A7ABBA84Q39447127-F2F86DE2-FE37-44BF-B825-7DDE3DB65CCAQ39860473-88425F3A-9B28-4EC8-B16A-A6818353E70CQ41829984-2D347BD3-0281-45AA-A577-47E6A272D6A4Q43105269-3A088125-2B50-4BC5-87C8-E21B7BBAE22FQ43122174-3E6E3BE9-2AFE-4E2A-B072-4A3043671DA9Q44542424-2C17CBE2-D9F6-4A4D-8485-F896A48FB1BBQ47122831-711EC2F8-10A0-48A9-8D07-C3AD8BBBF097Q47806060-C909AB09-1CE9-4B6F-9404-D00B178AB7E8Q50427017-CFAF8E91-76E2-43C8-B776-BB379037521BQ54109036-6D6C26D8-B431-4832-9B5D-94E1626AB188Q54364714-AF4493AC-8BB7-441C-BC0A-577C46746AC8Q54563760-D25F99B1-0A62-405F-8529-6965D02C4EA8Q59273028-D8AE52BB-DD68-4C38-8D26-EDBCA69497FF
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapy options in imatinib failures.
@en
Therapy options in imatinib failures.
@nl
type
label
Therapy options in imatinib failures.
@en
Therapy options in imatinib failures.
@nl
prefLabel
Therapy options in imatinib failures.
@en
Therapy options in imatinib failures.
@nl
P1433
P1476
Therapy options in imatinib failures.
@en
P2093
John F DiPersio
Pablo Ramirez
P304
P356
10.1634/THEONCOLOGIST.2007-0170
P577
2008-04-01T00:00:00Z